慢性中性粒细胞白血病预后因素的研究进展

阎拂蒙; 陈春燕

doi:10.12354/j.issn.1000-8179.2021.20210785

慢性中性粒细胞白血病预后因素的研究进展

doi: 10.12354/j.issn.1000-8179.2021.20210785

阎拂蒙,
陈春燕^,

山东大学齐鲁医院血液科（济南市250012）

详细信息

作者简介:
阎拂蒙：专业方向为血液病的诊断及治疗

通讯作者:
陈春燕　chency@sdu.edu.cn

计量
- 文章访问数: 245
- HTML全文浏览量: 19
- PDF下载量: 45
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-17
- 网络出版日期: 2021-08-25
- 刊出日期: 2021-09-30

Research progress on the prognostic factors of chronic neutrophilic leukemia

Fumeng Yan,
Chunyan Chen^,

Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China

More Information

Corresponding author: Chunyan Chen; E-mail: chency@sdu.edu.cn

摘要

摘要: 慢性中性粒细胞白血病（chronic neutrophilic leukemia，CNL）是一种少见类型的骨髓增殖性肿瘤。集落刺激因子3受体（colony-stimulating factor 3 receptor，CSF3R）突变为特征性分子学标志。目前，CNL的治疗尚无统一标准，靶向药物芦可替尼（ruxolitinib）等可改善部分患者的生存，异基因造血干细胞移植（allogeneic hematopoietic stem cell transplantation，allo- HSCT）仍然是唯一可能治愈的方法。随着CNL基因组学研究的不断深入，许多因素被证明与预后相关。本文综述了影响CNL患者预后的临床因素、细胞分子遗传学等因素，以期构建更为完善的预后评估系统，更好地指导患者的治疗。
- 慢性中性粒细胞白血病 /
- 集落刺激因子3受体 /
- 突变 /
- 风险模型 /
- 芦可替尼 /
- 预后
Abstract: Chronic neutrophilic leukemia(CNL) is a rare myeloproliferative neoplasm. Colony-stimulating factor 3 receptor (CSF3R) mutation has been confirmed as a biomarker of CNL. At present, there is no uniform standard for the treatment of CNL. The use of new therapeutic agents, such as ruxolitinib, has significantly improved the survival of patients. However, some patients still respond poorly to these agents. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the only possible curative therapy. Based on increasingly comprehensive gene expression profiling of CNL, many factors have been proven to be related to its prognosis. This article reviews the clinical and molecular cytogenetic variables that affect the prognosis of CNL patients to build a comprehensive prognostic schema and better guide the treatment of patients.
- chronic neutrophilic leukemia (CNL) /
- colony-stimulating factor 3 receptor (CSF3R) /
- mutation /
- risk model /
- ruxolitinib /
- prognosis

HTML全文

参考文献(30)

[1]	Elliott MA, Hanson CA, Dewald GW, et al. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature[J]. Leukemia, 2005, 19(2):313-317. doi: 10.1038/sj.leu.2403562
[2]	Szuber N, Finke CM, Lasho TL, et al. CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival[J]. Blood Cancer J, 2018, 8(2):21. doi: 10.1038/s41408-018-0058-7
[3]	Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML[J]. N Engl J Med, 2013, 368(19):1781-1790. doi: 10.1056/NEJMoa1214514
[4]	Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405. doi: 10.1182/blood-2016-03-643544
[5]	Szuber N, Elliott M, Tefferi A. Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management[J]. Am J Hematol, 2020, 95(2):212-224. doi: 10.1002/ajh.25688
[6]	Dao KT, Gotlib J, Deininger MMN, et al. Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia[J]. J Clin Oncol, 2020, 38(10):1006-1018. doi: 10.1200/JCO.19.00895
[7]	Elliott MA, Pardanani A, Hanson CA, et al. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia[J]. Am J Hematol, 2015, 90(7):653-656. doi: 10.1002/ajh.24031
[8]	Cui YJ, Jiang Q, Liu JQ, et al. The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia[J]. Chin J Hematol, 2017, 38(1):28-32.
[9]	郭玉洁,王艳,王立华,等.慢性中性粒细胞白血病患者的临床特征及预后分析[J].中国实验血液学杂志,2020,28(1):82-87.
[10]	Ruan GJ, Smith CJ, Day C, et al. A population-based study of chronic neutrophilic leukemia in the United States[J]. Blood Cancer J, 2020, 10(6):68. doi: 10.1038/s41408-020-0334-1
[11]	Venugopal S, Mascarenhas J. Chronic neutrophilic leukemia: current and future perspectives[J]. Clin Lymph Myeloma Leuk, 2019, 19(3):129-134. doi: 10.1016/j.clml.2018.11.012
[12]	Szuber N, Tefferi A. Chronic neutrophilic leukemia: new science and new diagnostic criteria[J]. Blood Cancer J, 2018, 8(2):19. doi: 10.1038/s41408-018-0049-8
[13]	Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia[J]. Leukemia, 2013, 27(9):1870-1873.
[14]	Price A, Druhan LJ, Lance A, et al. T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form[J]. Biochem Biophys Res Commun, 2020, 523(1):208-213. doi: 10.1016/j.bbrc.2019.12.030
[15]	Rohrabaugh S, Kesarwani M, Kincaid Z, et al. Enhanced MAPK signaling is essential for CSF3R-induced leukemia[J]. Leukemia, 2017, 31(8):1770-1778. doi: 10.1038/leu.2016.376
[16]	Maxson JE, Luty SB, Macmaniman JD, et al. The colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I[J]. Clin Cancer Res, 2016, 22(3):757-764. doi: 10.1158/1078-0432.CCR-14-3100
[17]	Zhang H, Reister Schultz A, Luty S, et al. Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations[J]. Leukemia, 2017, 31(12):2752-2760. doi: 10.1038/leu.2017.126
[18]	Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis[J]. Blood, 2019, 134(11):867-879.
[19]	Stoner RC, Press RD, Maxson JE, et al. Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy[J]. Leukemia, 2020, 34(6):1684-1688. doi: 10.1038/s41375-019-0688-1
[20]	Langabeer SE, Haslam K, Kelly J, et al. Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis[J]. Clin Transl Oncol, 2018, 20(3):420-423. doi: 10.1007/s12094-017-1722-2
[21]	Vishwakarma BA, Nguyen N, Makishima H, et al. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development[J]. Leukemia, 2016, 30(1):200-208. doi: 10.1038/leu.2015.200
[22]	Dao KH, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia[J]? Hematology Am Soc Hematol Educ Program, 2015, 2015(2):64-71.
[23]	Maxson JE, Tyner JW. Genomics of chronic neutrophilic leukemia[J]. Blood, 2017, 129(6):715-722.
[24]	Duployez N, Willekens C, Plo I, et al. Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia[J]. Blood, 2019, 134(26):2414-2416. doi: 10.1182/blood.2019003206
[25]	Menezes J, Cigudosa JC. Chronic neutrophilic leukemia: a clinical perspective[J]. Onco Targets and therapy, 2015, 8(23):83-90.
[26]	Hinze A, Rinke J, Hochhaus A, et al. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation[J]. Ann Hematol, 2021, 100(2):581-584. doi: 10.1007/s00277-020-04152-w
[27]	Lasho TL, Mims A, Elliott MA, et al. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib[J]. Leukemia, 2014, 28(6):1363-1365.
[28]	Coltro G, Rotunno G, Mannelli L, et al. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features[J]. Blood advances, 2020, 4(15):3677-3687.
[29]	Qian Y, Chen Y, Li X. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780 tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia[J]. Ann Hematol, 2021. [Epub ahead of print].
[30]	Lee SE, Jo I, Jang W, et al. T618I-mutated colony stimulating factor 3 receptor in chronic neutrophilic leukemia and chronic myelomonocytic leukemia patients who underwent allogeneic stem cell transplantation[J]. Ann Lab Med, 2015, 35(3):376-378. doi: 10.3343/alm.2015.35.3.376